<DOC>
	<DOCNO>NCT00840034</DOCNO>
	<brief_summary>The primary purpose study efficacy , safety , tolerability LY2216684 adjunctive treatment patient major depressive disorder ( MDD ) , identify partial responder adequate course treatment selective serotonin reuptake inhibitor ( SSRI ) ( defined history ) .</brief_summary>
	<brief_title>A Study Adjunctive Treatment Antidepressant Therapy Adults With Major Depressive Disorder</brief_title>
	<detailed_description>This 12 week multi-center , double-blind , placebo-controlled study efficacy LY2216684 augmentation selective serotonin reuptake inhibitor ( SSRIs ) patient MDD partial response treatment SSRI . While remain steady dose SSRI treatment entry study , patient randomly assign adjunctive treatment LY2216684 placebo 1:1 ratio 10 week acute treatment .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Serotonin Uptake Inhibitors</mesh_term>
	<mesh_term>Phenylethyl Alcohol</mesh_term>
	<criteria>Meet criterion MDD define DSMIVTR criterion Meet criterion partial response adequate course treatment define investigator 's opinion patient attain least minimal improvement current SSRI treatment Women childbearing potential must test negative pregnancy agree use reliable method birth control Grid Hamilton Rating Scale Depression ( GRIDHAMD17 ) total score great equal 16 study entry study enrollment SSRI treatment least 6 week stable dose least 2 week prior study enrollment Stated patient preference augmentation rather switch antidepressant treatment Are currently involve discontinue within last 30 day clinical trial involve offlabel use investigational drug Have previously complete withdrawn study study investigate LY2216684 Have currently additional ongoing DSMIVTR Axis 1 condition MDD Have anxiety disorder precede onset depression consider primary diagnosis within 1 year study entry Have current previous diagnosis Bipolar I II , psychotic depression , schizophrenia psychotic disorder Have history substance abuse within past 1 year Have Axis II disorder , judgment investigator , would interfere compliance protocol Have lack response current depressive episode 2 adequate course antidepressant therapy clinically appropriate dose least 4 week , judgment investigator , patient treatmentresistant depression Have history electroconvulsive therapy ( ECT ) , transcranial magnetic stimulation ( TMS ) , psychosurgery within last year Women pregnant breastfeeding Patients judge serious risk harm self others Have serious unstable medical illness Have diagnose medical condition could exacerbate noradrenergic agent include unstable hypertension , unstable heart disease , tachycardia tachyarrhythmia , narrow angle glaucoma , urinary hesitation retention Have history severe allergies 1 class medication multiple adverse drug reaction Have history seizure disorder ( febrile seizure ) Are take noradrenergic psychotropic medication , tricyclic antidepressant serotonin norepinephrine reuptake inhibitor ( SNRI ) Have receive treatment MAOI within 14 day prior study entry Require psychotropic medication sedative/hypnotic medication sleep Are take received treatment exclude medication within 7 day prior study enrollment Have thyroid stimulate hormone ( TSH ) level outside establish reference range Have initiate discontinue hormone therapy within previous 3 month prior enrollment Initiation change intensity psychotherapy nondrug therapy within 6 week prior enrollment A positive urine drug screen substance abuse study entry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2010</verification_date>
</DOC>